Jeff Schottenstein, MBA
A science-focused organization dedicated to ending gastric cancer, the Sara Schottenstein Foundation recently announced its launch and its new website, http://www.saraschottensteinfoundation.org. Founded by Jeff Schottenstein, MBA, a wealth management professional in San Francisco, the Sara Schottenstein Foundation supports innovative gastric cancer research, raises awareness, and champions patients and their caregivers. It also honors Sara Schottenstein (1967–2016), Jeff’s late wife, and her inspirational efforts to overcome gastric cancer.
A Continuing Mission
“I am thrilled to launch the Sara Schottenstein Foundation,” said Jeff Schottenstein. “Sara was a kind, compassionate, and beautiful individual, deeply committed to finding a cure for gastric cancer. At the end of her life, she took solace in knowing that our work would one day help other gastric cancer patients. We are driven to continue her mission to end this devastating disease and bring hope to patients, families, and researchers through the Sara Schottenstein Foundation.”
A wife, mother, and attorney, Sara was diagnosed with advanced gastric cancer in 2014, at the age of 47. During her nearly 2-year cancer journey, she and Jeff learned there were few approved treatments for gastric cancer. Their response was a commitment to exploring and supporting new potentially effective treatments.
The Sara Schottenstein Foundation Board of Directors includes Jeff Schottenstein as President; Stuart Wechsler, a wealth management executive, as Vice President; Michael Schottenstein, MD, a psychiatrist and Jeff’s brother, as Treasurer; and Julie Roth Novack, MBA, Chief Executive Officer and cofounder of PartySlate and Sara’s sister, as a board member.
Scientific Advisory Board members include Adam J. Bass, MD, of Columbia University Medical Center; Andrew T. Chan, MD, MPH, of Harvard T.H. Chan School of Public Health and Massachusetts General Hospital; Carlos U. Corvera, MD, FACS, of the University of San Francisco, Helen Diller Family Comprehensive Cancer Center; Pamela L. Kunz, MD, of Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital; Uri Ladabaum, MD, of Stanford University School of Medicine; and R. Jacob Vogelstein, PhD, of Catalio Capital Management.
“Sara was a champion in her own fight against cancer and on behalf of other cancer patients,” said Dr. Pamela Kunz, Leader of the GI Cancer Program at Yale Cancer Center. “It was a privilege to know her, and I’m proud to join the foundation that will honor Sara’s legacy in such a meaningful way. I look forward to working with the Sara Schottenstein Foundation to support patients and research that saves lives.”